The US Department of Health and Human Services (HHS) has awarded $590 million to Moderna to accelerate the development of mRNA vaccines against potential pandemic flu viruses. This funding is part of the Rapid Response Partnership Vehicle (RRPV) Consortium, supported by the Biomedical Advanced Research and Development Authority (BARDA).
With this investment, Moderna will focus on developing an H5N1 avian flu mRNA vaccine matching circulating strains in cows and birds, as well as expanding its clinical data for other pandemic-flu potential strains. The company will also conduct phase 3 trials for a novel mRNA-1018 investigational pandemic flu vaccine against H7N9 avian influenza.
Moderna has reported positive results from early trials, with a phase 1/2 study showing promising safety and immunogenicity data. The company plans to proceed with phase 3 studies and share its findings at an upcoming scientific meeting. Former HHS Assistant Secretary for Preparedness and Response Dawn O’Connell stated that mRNA technology will complement existing vaccine strategies, enabling faster development and better targeting of emerging viruses.
Source: https://www.cidrap.umn.edu/avian-influenza-bird-flu/hhs-awards-590-million-moderna-develop-mrna-vaccines-against-pandemic-flu